Friday, 6 November 2026European Markets

BW LPG Stock 12.28% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with BW LPG (BWLPG.OL) rising 12.28% to kr213.00 on Thursday while Oslo Børs Benchmark Index_GI rose 0.31% to kr1,428.10.

BW LPG's last close was kr189.70, 55.88% above its 52-week high of kr121.70.

About BW LPG

BW LPG Limited, an investment holding company, engages in ship owning and chartering activities worldwide. The company operates through Shipping and Product Services segments. The company involved in the transportation of liquefied petroleum gas to oil companies, and trading and utility companies. It also offers integrated liquified petroleum gas (LPG) delivery services and support; wholesale and trade of LPG; and management services. It owns and operates LPG vessels and a fleet of very large gas carriers. The company was formerly known as BW Gas LPG Holding Limited and changed its name to BW LPG Limited in September 2013. BW LPG Limited was founded in 1935 and is headquartered in Singapore.

Earnings Per Share

As for profitability, BW LPG has a trailing twelve months EPS of kr37.03.

PE Ratio

BW LPG has a trailing twelve months price to earnings ratio of 5.75. Meaning, the purchaser of the share is investing kr5.75 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.16%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 206.6%, now sitting on 2.17B for the twelve trailing months.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on May 26, 2023, the estimated forward annual dividend rate is 39.9 and the estimated forward annual dividend yield is 33.62%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BW LPG's stock is considered to be oversold (<=20).

More news about BW LPG (BWLPG.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com